TipRanks
Bristol-Myers Squibb (MX:BMY)
:BMY
Mexico Market
BMY
Bristol-Myers Squibb
RESEARCH TOOLSreports

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

BMY Analyst Ratings

Moderate Buy
22Ratings
Moderate Buy
9 Buy
12 Hold
1 Sell
Based on 22 analysts giving stock ratings to
Bristol-Myers
Squibb
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BMY Stock 12 Month Forecast

Average Price Target

$1,234.40
▲(10.20% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is $1,234.40 with a high forecast of $1,493.01 and a low forecast of $765.17. The average price target represents a 10.20% change from the last price of $1,120.18.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"764":"$764","1129":"$1,129","1494":"$1,494","946.5":"$946.5","1311.5":"$1,311.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1493.0108432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.49K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1234.4000364314284,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.23K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":765.16805714,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$765.17</span>\n  </div></div>","useHTML":true}}],"tickPositions":[764,946.5,1129,1311.5,1494],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1103.568,1133.5251417846155,1163.4822835692307,1193.4394253538462,1223.3965671384615,1253.353708923077,1283.3108507076922,1313.2679924923077,1343.225134276923,1373.1822760615385,1403.1394178461537,1433.0965596307692,1463.0537014153847,{"y":1493.0108432,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1103.568,1113.6320028024174,1123.6960056048351,1133.7600084072526,1143.8240112096703,1153.8880140120878,1163.9520168145054,1174.016019616923,1184.0800224193406,1194.144025221758,1204.2080280241757,1214.2720308265932,1224.3360336290107,{"y":1234.4000364314284,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1103.568,1077.5372351646154,1051.5064703292308,1025.4757054938461,999.4449406584615,973.4141758230769,947.3834109876923,921.3526461523077,895.321881316923,869.2911164815384,843.2603516461538,817.2295868107692,791.1988219753846,{"y":765.16805714,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":816.296,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":813.105,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":854.239,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":931.723,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":910.31,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1038.029,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1079.805,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1028.479,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":983.464,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":953.618,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1114.455,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1118.414,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1103.568,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,493Average Price Target$1,234Lowest Price Target$765.17
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on MX:BMY
Emily Field
Barclays
Barclays
$1,399.7
Buy
24.95%
Upside
Reiterated
10/29/26
Analysts Offer Insights on Healthcare Companies: Avantor (NYSE: AVTR), Bristol-Myers Squibb (NYSE: BMY) and Align Tech (NASDAQ: ALGN)
RBC Capital Analyst forecast on MX:BMY
Trung Huynh
RBC Capital
RBC Capital
$1,194.41
Hold
6.63%
Upside
Reiterated
10/27/26
Bristol-Myers Squibb (BMY) Gets a Hold from RBC Capital
Piper Sandler Analyst forecast on MX:BMY
David Amsellem
Piper Sandler
Piper Sandler
$1,455.69
Buy
29.95%
Upside
Reiterated
10/27/26
Bristol Myers price target lowered to $78 from $82 at Piper SandlerBristol Myers price target lowered to $78 from $82 at Piper Sandler
Scotiabank Analyst forecast on MX:BMY
Louise Chen
Scotiabank
Scotiabank
$1,119.76
Hold
-0.04%
Downside
Reiterated
10/26/26
Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), Bristol-Myers Squibb (NYSE: BMY) and Parabilis Medicines, Inc. (NASDAQ: PBLS)
Bernstein Analyst forecast on MX:BMY
Courtney Breen
Bernstein
Bernstein
$1,138.42
Hold
1.63%
Upside
Reiterated
10/25/26
Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
Goldman Sachs Analyst forecast on MX:BMY
Asad Haider
Goldman Sachs
Goldman Sachs
$1,175.75
Hold
4.96%
Upside
Assigned
10/19/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (NASDAQ: BMRN), Eli Lilly & Co (NYSE: LLY) and Bristol-Myers Squibb (NYSE: BMY)
Truist Financial Analyst forecast on MX:BMY
Srikripa Devarakonda
Truist Financial
Truist Financial
$1,306.38
Buy
16.62%
Upside
Reiterated
10/13/26
Truist Financial Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY)
Citi Analyst forecast on MX:BMY
Geoff Meacham
Citi
Citi
$1,306.38
Hold
16.62%
Upside
Reiterated
10/13/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Bristol-Myers Squibb (NYSE: BMY) and Edgewise Therapeutics (NASDAQ: EWTX)
Wells Fargo Analyst forecast on MX:BMY
Mohit Bansal
Wells Fargo
Wells Fargo
$1,213.07→$1,119.76
Hold
-0.04%
Downside
Assigned
10/13/26
Analysts Conflicted on These Healthcare Names: Resmed (NYSE: RMD) and Bristol-Myers Squibb (NYSE: BMY)
Jefferies Analyst forecast on MX:BMY
Akash Tewari
Jefferies
Jefferies
$1,362.37→$1,418.36
Buy
26.62%
Upside
Reiterated
10/12/26
Bristol Myers price target raised to $76 from $73 at JefferiesBristol Myers price target raised to $76 from $73 at Jefferies
BMO Capital Analyst forecast on MX:BMY
Evan Seigerman
BMO Capital
BMO Capital
$1,119.76
Hold
-0.04%
Downside
Reiterated
10/12/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and AxoGen (NASDAQ: AXGN)
Morgan Stanley Analyst forecast on MX:BMY
Terence Flynn
Morgan Stanley
Morgan Stanley
$765.17
Sell
-31.69%
Downside
Reiterated
10/12/26
Risk-Reward Unfavorable for Bristol-Myers Squibb: Sell Rating Reiterated with Unchanged $41 Price Target
William Blair Analyst forecast on MX:BMY
Matt Phipps
William Blair
William Blair
―
Hold
―
Reiterated
10/12/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Bristol-Myers Squibb (NYSE: BMY) and Palvella Therapeutics (NASDAQ: PVLA)
Bank of America Securities Analyst forecast on MX:BMY
Jason Gerberry
Bank of America Securities
Bank of America Securities
$1,325.05→$1,231.73
Buy
9.96%
Upside
Reiterated
10/09/26
Bristol Myers price target lowered to $66 from $71 at BofABristol Myers price target lowered to $66 from $71 at BofA
UBS Analyst forecast on MX:BMY
Michael Yee
UBS
UBS
$1,493.01
Buy
33.28%
Upside
Reiterated
10/09/26
Analysts' Top Healthcare Picks: Insmed (INSM), Bristol-Myers Squibb (BMY)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on MX:BMY
Emily Field
Barclays
Barclays
$1,399.7
Buy
24.95%
Upside
Reiterated
10/29/26
Analysts Offer Insights on Healthcare Companies: Avantor (NYSE: AVTR), Bristol-Myers Squibb (NYSE: BMY) and Align Tech (NASDAQ: ALGN)
RBC Capital Analyst forecast on MX:BMY
Trung Huynh
RBC Capital
RBC Capital
$1,194.41
Hold
6.63%
Upside
Reiterated
10/27/26
Bristol-Myers Squibb (BMY) Gets a Hold from RBC Capital
Piper Sandler Analyst forecast on MX:BMY
David Amsellem
Piper Sandler
Piper Sandler
$1,455.69
Buy
29.95%
Upside
Reiterated
10/27/26
Bristol Myers price target lowered to $78 from $82 at Piper SandlerBristol Myers price target lowered to $78 from $82 at Piper Sandler
Scotiabank Analyst forecast on MX:BMY
Louise Chen
Scotiabank
Scotiabank
$1,119.76
Hold
-0.04%
Downside
Reiterated
10/26/26
Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), Bristol-Myers Squibb (NYSE: BMY) and Parabilis Medicines, Inc. (NASDAQ: PBLS)
Bernstein Analyst forecast on MX:BMY
Courtney Breen
Bernstein
Bernstein
$1,138.42
Hold
1.63%
Upside
Reiterated
10/25/26
Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
Goldman Sachs Analyst forecast on MX:BMY
Asad Haider
Goldman Sachs
Goldman Sachs
$1,175.75
Hold
4.96%
Upside
Assigned
10/19/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (NASDAQ: BMRN), Eli Lilly & Co (NYSE: LLY) and Bristol-Myers Squibb (NYSE: BMY)
Truist Financial Analyst forecast on MX:BMY
Srikripa Devarakonda
Truist Financial
Truist Financial
$1,306.38
Buy
16.62%
Upside
Reiterated
10/13/26
Truist Financial Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY)
Citi Analyst forecast on MX:BMY
Geoff Meacham
Citi
Citi
$1,306.38
Hold
16.62%
Upside
Reiterated
10/13/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Bristol-Myers Squibb (NYSE: BMY) and Edgewise Therapeutics (NASDAQ: EWTX)
Wells Fargo Analyst forecast on MX:BMY
Mohit Bansal
Wells Fargo
Wells Fargo
$1,213.07→$1,119.76
Hold
-0.04%
Downside
Assigned
10/13/26
Analysts Conflicted on These Healthcare Names: Resmed (NYSE: RMD) and Bristol-Myers Squibb (NYSE: BMY)
Jefferies Analyst forecast on MX:BMY
Akash Tewari
Jefferies
Jefferies
$1,362.37→$1,418.36
Buy
26.62%
Upside
Reiterated
10/12/26
Bristol Myers price target raised to $76 from $73 at JefferiesBristol Myers price target raised to $76 from $73 at Jefferies
BMO Capital Analyst forecast on MX:BMY
Evan Seigerman
BMO Capital
BMO Capital
$1,119.76
Hold
-0.04%
Downside
Reiterated
10/12/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and AxoGen (NASDAQ: AXGN)
Morgan Stanley Analyst forecast on MX:BMY
Terence Flynn
Morgan Stanley
Morgan Stanley
$765.17
Sell
-31.69%
Downside
Reiterated
10/12/26
Risk-Reward Unfavorable for Bristol-Myers Squibb: Sell Rating Reiterated with Unchanged $41 Price Target
William Blair Analyst forecast on MX:BMY
Matt Phipps
William Blair
William Blair
―
Hold
―
Reiterated
10/12/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Bristol-Myers Squibb (NYSE: BMY) and Palvella Therapeutics (NASDAQ: PVLA)
Bank of America Securities Analyst forecast on MX:BMY
Jason Gerberry
Bank of America Securities
Bank of America Securities
$1,325.05→$1,231.73
Buy
9.96%
Upside
Reiterated
10/09/26
Bristol Myers price target lowered to $66 from $71 at BofABristol Myers price target lowered to $66 from $71 at BofA
UBS Analyst forecast on MX:BMY
Michael Yee
UBS
UBS
$1,493.01
Buy
33.28%
Upside
Reiterated
10/09/26
Analysts' Top Healthcare Picks: Insmed (INSM), Bristol-Myers Squibb (BMY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AXGNAxoGen
SIBNSI-Bone
AORTArtivion
PHVSPharvaris
HELPHelus Pharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol-Myers Squibb

3 Months
Srikripa DevarakondaTruist Financial
Success Rate
13/17 ratings generated profit
76%
Average Return
+9.48%
Copying Srikripa Devarakonda's trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +9.48% per trade.
1 Year
David AmsellemPiper Sandler
Success Rate
11/13 ratings generated profit
85%
Average Return
+18.85%
Copying David Amsellem's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +18.85% per trade.
2 Years
Srikripa DevarakondaTruist Financial
Success Rate
16/17 ratings generated profit
94%
Average Return
+27.32%
Copying Srikripa Devarakonda's trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +27.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMY Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
19
22
21
16
18
Hold
27
30
28
33
35
Sell
1
2
2
3
4
Strong Sell
0
0
0
0
0
total
47
54
51
52
57
In the current month, BMY has received 18 Buy Ratings, 35 Hold Ratings, and 4 Sell Ratings. BMY average Analyst price target in the past 3 months is 1,234.40.
Each month's total comprises the sum of three months' worth of ratings.

BMY Financial Forecast

BMY Earnings Forecast

Next quarter’s earnings estimate for BMY is $30.31 with a range of $27.81 to $32.66. The previous quarter’s EPS was $25.19. BMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.
Next quarter’s earnings estimate for BMY is $30.31 with a range of $27.81 to $32.66. The previous quarter’s EPS was $25.19. BMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.

BMY Sales Forecast

Next quarter’s sales forecast for BMY is $237.21B with a range of $227.84B to $243.45B. The previous quarter’s sales results were $243.90B. BMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.
Next quarter’s sales forecast for BMY is $237.21B with a range of $227.84B to $243.45B. The previous quarter’s sales results were $243.90B. BMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.

BMY Stock Forecast FAQ

What is MX:BMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is 1,234.40.
    What is MX:BMY’s upside potential, based on the analysts’ average price target?
    Bristol-Myers Squibb has 10.20% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Bristol-Myers Squibb a Buy, Sell or Hold?
          Bristol-Myers Squibb has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 12 hold ratings and 1 sell ratings.
            What is Bristol-Myers Squibb’s share price target?
            The average share price target for Bristol-Myers Squibb is 1,234.40. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $1,493.01 ,and the lowest forecast is $765.17. The average share price target represents 10.20% Increase from the current price of $1,120.18.
              What do analysts say about Bristol-Myers Squibb?
              Bristol-Myers Squibb’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of Bristol-Myers Squibb?
                To buy shares of MX:BMY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.